Hirata-Koizumi Mutsuko, Saito Mitsuo, Urano Tsutomu, Miyake Shinji, Hasegawa Ryuichi
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2005(123):12-8.
In clinical practice, one drug is frequently used in combination with one or more other drugs, rather than as a sole regimen, and therefore healthcare providers need to carefully consider drug interactions. As mechanisms of drug interactions, metabolic enzymes of drugs are seen as one of the most likely interactive sites, where a majority of drugs are metabolized by cytochrome P450 (CYP). For this reason, providing appropriate information on CYP in package inserts is of grave importance. In fact, the package insert is the primary tool for supplying information on drugs to healthcare providers. The present study was designed to determine how many package inserts of prescription drugs marketed in Japan were providing CYP information. We searched the April 2003 version of "Drugs in Japan DB," which listed 2,022 prescription drugs, and found that only 239 package inserts (11.8%) mentioned CYP information and that only 194 (9.6%) specified CYP isozymes. To assess the improvement of package inserts, we searched "Drugs in Japan DB" from the January 2000 version to the April 2003 version. We found that CYP information had increased year by year (eg, 7.8-11.8% annually). For newly approved drugs, an analysis of the relationship between approval year and CYP information in package inserts (April 2003 version) revealed that recently approved drugs had more CYP information (eg, 45.5-51.3% of drugs in 1999-2002, compared to 6.8-26.1% in 1991-1996). A search for regulatory review documents for new drugs approved from 1999 to 2002 suggested that this recent improvement could be related to the increased number of studies identifying CYP isozymes involved in the metabolism or interaction with other drugs. Another reason for the recent improvement may be the fact that the guideline for package inserts for prescription drugs was revised in 1997, and the guidelines for drug interaction and pharmacokinetic studies were published between 1997 and 1999.
在临床实践中,一种药物常常与一种或多种其他药物联合使用,而非单独作为一种治疗方案,因此医疗保健提供者需要仔细考虑药物相互作用。作为药物相互作用的机制,药物的代谢酶被视为最可能的相互作用位点之一,大多数药物在此被细胞色素P450(CYP)代谢。因此,在药品说明书中提供有关CYP的适当信息至关重要。事实上,药品说明书是向医疗保健提供者提供药物信息的主要工具。本研究旨在确定在日本销售的处方药的药品说明书中有多少提供了CYP信息。我们检索了2003年4月版的《日本药品数据库》,其中列出了2022种处方药,发现只有239份药品说明书(11.8%)提及了CYP信息,只有194份(9.6%)明确指出了CYP同工酶。为评估药品说明书的改进情况,我们检索了2000年1月版至2003年4月版的《日本药品数据库》。我们发现CYP信息逐年增加(例如,每年增加7.8 - 11.8%)。对于新批准的药物,对2003年4月版药品说明书中批准年份与CYP信息之间的关系进行分析发现,近期批准的药物有更多的CYP信息(例如,1999 - 2002年批准的药物中有45.5 - 51.3%,而1991 - 1996年批准的药物中为6.8 - 26.1%)。对1999年至2002年批准的新药的监管审评文件进行检索表明,近期的这种改进可能与确定参与药物代谢或与其他药物相互作用的CYP同工酶的研究数量增加有关。近期改进的另一个原因可能是1997年修订了处方药药品说明书指南,并且在1997年至1999年期间发布了药物相互作用和药代动力学研究指南。